Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise
⇨ A collaboration between Sanofi and the NIH led to the development of a three-pronged antibody that has shown promise in a primate model for HIV. The therapy binds to three different sites on the virus, which makes it harder for HIV to escape. The investigators are now planning human trials to see how this could work in patients.
⇨ Shares of Akari $AKTX shot up more than 80% Thursday morning as investors reacted to their plans to launch a Phase III program. The biotech has been under a cloud since it was forced to restate responses tracked in an early-stage study, triggering the abrupt exit of its CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
